期刊文献+

Smart nanocarriers as therapeutic platforms for bladder cancer 被引量:1

原文传递
导出
摘要 Although patients benefit from surgical transurethral resection of bladder cancers,some niduses are missed or incompletely resected,and small malignant lesions may recur.Intravesical chemotherapy and immunotherapy are universally accepted as adjuvant treatments after surgery to avoid recurrence and progression.However,these treatments still have limitations,including an insufficient retention period,inefficient permeability of chemotherapeutic agents,and dilution of the agents by urine.Nanostructure-based smart therapeutic platforms can be tailored to be responsive to internal or external stimuli to ameliorate this situation.This unparalleled capability empowers the precise aggregation of stimulus–responsive nanocarriers in the target regions,namely,the tumors,and subsequent release of the anticancer materials.This review summarizes the current nanostructure-based therapeutic platforms,especially stimulus–responsive nanocarriers,and highlights their benefits and limitations in bladder cancer therapy.Novel innovations in nanotechnology have undoubtedly arrived at a new height and have become useful for practical applications.Nanotechnology will positively promote the development of anticancer agents not only for bladder cancer but also for other solid tumors.
出处 《Nano Research》 SCIE EI CSCD 2022年第3期2157-2176,共20页 纳米研究(英文版)
基金 the National Natural Science Foundation of China(Nos.21704104 and 81772754) Shenzhen Science and Technology Innovation Commission(Nos.RCYX20200714114645131 and JCYJ20190809164617205) Guangdong Basic and Applied Basic Research Foundation(Nos.2020A1515011443 and 2021A1515010669) Major Basic Research and Cultivation Program of Natural Science Foundation of Guangdong Province(No.2017A03038009) the Fundamental Research Funds for the Central Universities,Sun Yat-sen University(No.20ykpy17) Sanming Project of Medicine in Shenzhen(No.SZSM202011011) Research Start-up Fund of Part-time PI,SAHSYSU(No.ZSQYJZPI202003).
  • 相关文献

参考文献10

二级参考文献58

  • 1Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229.
  • 2Holohan, C.; Van Schaeybroeck, S.; Longley, D. B.; Johnston, P. G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 2013, 13, 714-726.
  • 3Wiemik, P. H. Anthracyclines: Current status and new development. Academic Press, NY 1980.
  • 4Chatterjee, K.; Zhang, J. Q.; Honbo, N.; Karliner, J. S. Doxorubicin cardiomyopathy. Cardiol. 2010, 115, 155-162.
  • 5Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe,C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
  • 6Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of atp-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
  • 7Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch,1.L. et al. Structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323, 1718-1722.
  • 8Bums, J. S.; Abdallah, B. M.; Guldberg, P.; Rygaard, J.; Schroder, H. D.; Kassem, M. Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res. 2005, 65, 3126-3135.
  • 9Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-760.
  • 10Hughes, B. Antibody-drug conjugates for cancer: Poised to deliver? Nat. Rev. Drug Discov. 2010, 9, 665-667.

共引文献92

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部